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sn2  Substitution Nucleophilic 
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Spinal Muscular Atrophy is an autosomal recessive neurodegenerative disorder, caused by the 
lack of SMN genes. Previous work done by Laboratory for Drug Discovery in 
Neurodegeneration (LDDN) at Brigham and Women’s Hospital optimized a lead compound 
from screening of 115,000 compounds for treatment of SMA. With the substantial amount of 
medical drugs involving imidazole as a component, this work focuses on the synthesis of 
analogs where the heterocycle in the lead compound is exchanged with imidazole. 
 
The synthesis of 3-chloro-4-fluoro-N-(2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazol-4-
yl)benzamide was attempted by several different routes. The first involved attaching a ketone 
by lithiation of the central methylated imidazole carbon. Five different methods of nitration 
were used thereafter, in an attempt to nitrate the 4-position on the heterocycle. Although 
results were promising from one of the nitrations, the product could not be isolated and larger 
scale repetition of the reaction yielded no product.   
 
The second route involved methylation of 4(5)-nitroimidazole, followed by a reduction. The 
resulting amine was collected in high yield but deteriorated over time. Three different 
protective groups were attempted, but all reactions were plagued by low or no yield. Despite 
this, the BOC protected amine was attempted lithiated, but the notoriously low yield of 
lithiations made the route unsustainable. Using formic acid, the amine was amide protected, 
but the resulting compound proved insoluble in common solvents used for n-BuLi. The amine 
was instead amidated resulting in 3-chloro-4-fluoro-N-(1-methyl-1H-imidazol-4-yl)-
benzamide in sufficient yield. The compound was lithiated successfully. However, it was 
directed to the backbone, resulting in a different analog of the target molecule. In an attempt 
to direct the lithiation, 1-methyl-4-nitro-1H-imidazol was brominated. The resulting 
compound gave poor results in both a Grignard reaction, and with n-BuLi. Reduction of the 
nitro group with Pd(OH)2/C and by iron also failed. Methyl 1-methyl-1H-imidazole-4-
carboxylate also was attempted to be lithiated, but with no success. 
 
The analog of the target molecule was sent, together with its precursor, for testing in the SMA 
assay. Both compounds proved inactive. 
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1 Spinal Muscular Atrophy[1] 
 
Spinal Muscular Atrophy is an autosomal recessive neurodegenerative disorder, characterized 
by progressive muscle wasting over time and eventual loss of muscle function. It is one of the 
leading causes of infant mortality in the world, affecting between 1 in 6,000 to 1 in 11,000 
childbirths. There are four different types of SMA, characterized by the amount of SMN2 
gene copies, and, as a result, the age in which the disease manifests. Patients carrying type 1, 
also known as “Werdniug-Hoffman” disease, only have 2-3 copies of the SMN2 gene. 
Children affected by the disease typically seem to have normal strength at birth but shows 
signs of weakness within months or weeks. Within six months of birth, these children cannot 
sit unsupported due to lack of muscle function. Death due to respiratory failure often ensues 
within two years. Type 2 patients carry 3-4 copies of SMN2 and are able to sit unsupported. 
Type 3 and 4 are milder forms, where the patients carry more copies of the SMN2 gene, with 
onset much later in life. All four variants of the disease leave the patient without any of the 




Figure 1: Transcription of the SMN genes and following translation. Picture taken 
from “Small Molecules in Development for the Treatment of Spinal Muscular 
Atrophy”[1] 
 
The first cases of SMA were reported in 1890, by Guido Werdnig and Johan Hoffman. Their 
studies showed that the patients severely lacked α-motor neurons from the anterior horn of the 
spinal cord. A study done in 1995, mapped the SMA genes to chromosome 5q13, in which 
two nearly identical genes, SMN1 and SMN2, encoded for the same SMN protein. Although 
SMN1 and SMN2 transcribe mRNA at the same speed, approximately 85% of the SMN2 
transcripts result in truncated SMN proteins with no effect, due to a nucleotide difference 
from C to T of exon 7, encoding residue 840. This difference means the SMN2 gene generates 






2 Previous Work 
 
Several repurposed drugs that already have proven medicinal effects, like valproic acid, 
albuterol, and hydroxyurea, have been clinically tested, but none gave convincing 
improvement in the muscle function or survival in SMA. Although the production of the 
SMN protein was mildly increased by these compounds, many genes are edited by them, and 
the long term effects are uncertain. Despite this, prescription of these substances often is 
necessary in severe cases. [2] 
 
Other than repurposed drugs, there are ten different preclinical agents for SMA treatment 
currently in development; amongst others, gene therapy and antisense oligonucleotides. One 
of them is novel, small molecule development. There are currently six small molecules in 
development for the treatment of SMA. The LDDN and the Androphy group at Indiana 
University have, in a collaborative project,  previously combined the SMN promoter with 
exons 1-6 and an exon 7 splicing cassette in a single construct with a luciferase reporter to 
identify compounds that can potentially increase the SMN2 transcription, increase the SMN2 
life time, or increase exon 7 inclusion.[3] 
 
A total of 115.000 compounds were screened using this SMN2 reporter assay, resulting in two 
hit compounds. LDN-75654 (25) was shown to increase the survivability of the SMN2 
protein, and LDN-76070 (28) was shown to increase the transcription of the protein. 
Compound 25 gave a 3.4-fold increase in the luciferase activity of the assay with an EC50 of 2 
µM. The molecule was compliant with Lipinski’s rules for drug-like molecules, but, when 
tested in mice, 25 did not elevate levels of SMN2 protein consistently in the brain or spinal 
tissue. This was seen to be caused by low metabolic stability and poor solubility. Hence, 
modification of 25 was done to improve this.[3] 




Chart 1: Hits from screening 
 
The LDDN reported in 2017 its results of optimization of the hit compounds[4]. The aryl 
group was modified, and, while substitution of the halides with other electron-withdrawing 
groups gave a decrease in potency, removal of both the 4-chloro and 4-fluoro increased the 
potency. Changing the phenyl ring with different heterocycles was also attempted, but the 
results were disappointing. The groups were comparable at best, with analogs with a 
heteroatom at the 2-position generally performing decently, while those at the 3- or 4-position 
doing worse.[4] 
 
Figure 2: Relevant sites of interest for optimizing 
While keeping the isoxazole and 3-chloro-4-fluorophenyl rings constant, different substituents 
were examined in the 5-position. Unsubstituted methyl and ethyl groups were attempted, but 
gave significant decreases in activity. The bulkier sec-butyl and tert-butyl substituents gave 
comparable results to the isopropyl group. The original isopropyl group was, hence, seen as 
optimal 5-substituent in terms of increasing SMN2 expression. The amide linker then was 
exchanged for esters, thioamides, amines, and reverse amides, without yielding better results 
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than the original amide. In a last set of compounds, the effect of both reversal of the amide 
bond and different N-linked heterocycles were measured. Although the reversed amide 
decreased the potency, thiazole significantly increased activity, especially the one substituted 
with cyclobutanol.[4] 
 
The most promising compounds were tested for solubility, and in the isoxazole series, only 
4m proved to have favorable stability. In addition, the 5-cyclobutyl alcohol substituted 27 was 
proven to do well.[4] 
 
 
Chart 2: Promising compounds from optimization 
 
These compounds were tested on human cells derived from a severe SMA patient. Both 
compounds gave approximately a 2-fold increase in SMN protein. However, when the 
synthesis of 4m was scaled up for preliminary mouse PK and efficacy experiments and given 
to mouse at 20 mg/kg, the compound was found only in trace amounts in the plasma. 4m was 
incubated in herparin sodium-treated mouse plasma at 37OC for 60 min. From the results, it 
was apparent that 4m was unstable in mouse plasma, with the amide bond susceptible to 
hydrolysis. The amide then was methylated, in an attempt to increase the stability in plasma, 
with significant success. 27 was tested for preliminary mouse PK experiments, and high levels 
were recorded in the brain and plasma. When administered orally, the results were more 
moderate, which at first was thought to be from decomposition of the molecule from stomach 
acid. However, when tested in 0.1 N and 1 N HCl over 24 hours, only 5% were decomposed 





Since 4m, the most promising of the isoxazole compounds, showed such unfavorable PK 
characteristics, it did not fit the criteria for further investigation. Despite low solubility when 
administered orally, 27 showed good brain and plasma exposure, and was chosen to 






























3 Imidazole in Medicinal Chemistry 
 
 
Imidazole is a five membered aromatic heterocycle abundantly present in nature and synthetic 
molecules. It is characterized by its two nitrogen, and its amphoteric and highly polar abilities. 
It exists in two equivalent tautomeric forms, where the hydrogen can be located on both of the 
nitrogen atoms.[5] It can both accept and donate a proton, and it easily forms weak 
interactions. The molecule was first reported in 1858, by German-British chemist Heinrich 
Debus, although some imidazole derivatives had been discovered as early as 1840.[6] Since 
then, the development of imidazole-based compounds has been a rapidly expanding field, due 
to its potential as agrochemicals, medicinal drugs, supramolecular ligands, biomimetic 
catalysts, and more.[7] 
 
 
Figure 3: Resonance forms of imidazole 
 
The special structural characteristics of imidazole are beneficial for its derivatives, as it helps 
them bind with a variety of enzymes and receptors in biological systems, via hydrogen bonds, 
coordination, ion-dipole, hydrophobic effects, van der Walls forces, and more. These 
phenomena make nature select the molecule in many vital compounds, like histamine and 
deoxyribonucleic acid (DNA). [8] 
 
 




The introduction of imidazole into compounds of interest can be a good way to increase the 
solubility of the compound, as the two nitrogen atoms easily form hydrogen bonds. It also can 
be used as potential isosteres for triazole, oxazole, pyrazole, thiazole, and other heterocycles, 
since it has multiple binding sites capable of coordinating with inorganic metal ions and 
interacting with organic molecules via noncovalent bonds to produce supramolecular drugs. 
These compounds carry not only the traits of imidazole, but also the advantages of numerous 
supramolecular drugs. Imidazole also can interact with a diverse set of anions and cations, as 
well as biological molecules in the body. It has, therefore, often been incorporated into 
fluorescent skeletons to create diagnostic agents. [9] 
  
A large number of imidazole based compounds are currently used as clinical drugs, such as 
dacarbazine, zoledronic acid, and azathioprine as anticancer drugs, and metronidazole and 














4 Aim of Study 
 
Encouraged by the promising activity of compound 27 and 4m, the aim of this project is to 
develop analogs of the previously synthesized 27 that can increase activity even more. We 
propose that this can be done by exchanging the heterocycle with imidazole. Imidazole has a 
long history of use within medicinal chemistry, and our hypothesis is not only increased 
activity, but that imidazole will offer the completed molecule more water solubility. As a 
starting point, attaching the same substituents as used for 27, which has earlier proven to give 
promising activity, will be the goal. 
 
 
Figure 5: Target Molecule 
 
If successful, analogs with substituents that previously gave varying results can be 
synthesized. With benzoyl readily available, imidazole and early derivates like 4-
nitroimidazole and 1-methylimidazole will be natural starting points. Imidazole chemistry 
historically has given surprising results to familiar reactions and attaching the substituents at 
the 2-position and 4-position without one interfering with the other will be quintessential.[9] 
 
If the target molecule, or any analogy close to it, is successfully synthesized, the LDDN will 
send it to the Androphy group at Indiana University for testing in the assay previously 










5.1 Nuclear Magnetic Resonance 
 
Nuclear magnetic resonance spectroscopy is a technique commonly employed in organic 
chemistry to observe local magnetic fields around magnetic nuclei. By placing the sample in a 
magnetic field, an NMR signal is produced by excitation of the nuclei sample with radio 
waves into nuclear magnetic resonance, which is detected using radio receivers.[10] The 
NMR active nuclei absorb electromagnetic radiation at a frequency that is characteristic for 
the isotope. The energy radiation absorbed, the resonant frequency, and the intensity of the 
signal are proportional to the magnetic field.[11] 
 
The resonance frequency of a molecule is changed by the intramolecular magnetic field 
around an atom. This gives information about the molecule and its individual functional 
groups. [12] The high accuracy of measurement makes it possible to differentiate small 
changes in chemical shift. Because of this, NMR spectroscopy is regarded as the definite 
method of identifying organic molecules.[12] 
 
Figure 6: The inside of a modern cryomagnet[13] 
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NMR can be used to measure any sample that contains nuclei possessing spin. The two most 
common methods however, are proton NMR, and carbon-13 NMR[14]. The relatively low 
abundance of carbon-13 makes the cryomagnet require more scans for a complete spectrum. 
The samples are dissolved in a deuterated solvent to avoid detection of the solvent atoms, and 
between 2-50 mg of a substance is required, depending on which kind of spectrum is required. 
 
The method was developed by the Purcell group at Harvard University and the Bloch group at 
Stanford University at the same time, independently. The method has been in use ever since, 
with cryomagnets being most common at universities. [15] 
 
5.2 Mass Spectrometry 
 
Mass spectrometry has been in use since 1918 and is a common way of characterizing pure 
samples as well as complex samples.[16] It measures mass-to-charge ions and plots the results 
as a mass spectrum. A typical mass spectrometer consists of three parts: and ion source, a 
mass analyzer, and a detector[17]. Because of the high sensitivity of the MS instrument, 
purification using Liquid Chromatography or Gas Chromatography beforehand is often 
used.[18]  
 
There is a wide range of techniques used to ionize the compound, which can be split in to two 
categories, hard and soft ionization.[19] Hard ionization techniques bestow large amounts of 
residual energy into the subject molecule, usually leading to a large amount of 
fragmentation.[17] Detailed knowledge about fragmentation is necessary to deduce the 
composition of the sample. Electron ionization (EI) is the most used hard ionization 
technique.[20] Soft ionization methods involve bestowing a much lower amount of energy 
onto the compound, leading to little fragmentation. Electrospray ionization (ESI) and 









) 𝑎 = 𝐸 + 𝑣 × 𝐵 
Equation 1: Motion for charged particles. m is mass, a is acceleration, Q is the ion 
charge, E is the electric field, v × B is vector cross product 
 
Taking advantage of the mass-to-charge ration, a mass analyzer separates the compounds for 
the detector based on equation 1.[19] Together with the particle’s initial conditions, its motion 
in time and space and can be expressed in m/Q. All mass analyzers depend on this equation, 
but is separated by their mass resolving power, their mass accuracy, their mass range, speed 
and price, amongst others[21]. Many instruments use two or more mass analyzers after each 
other for increased accuracy, usually referred to as tandem mass spectroscopy.[20] The most 
common are Time-of-Flight that uses an electric field to accelerate ions through a given 
potential, before measuring the time they take to reach the detector, and Quadrupole mass 
analyzer, that uses oscillating electric fields to stabilize or destabilize the paths of ions passing 
a radio frequency quadrupole field created between 4 parallel rods.[17] [21] Only ions with a 
preset mass/charge ratio are passed through at a given time.[19] 
 
Both the charge and the current produced by the bypassing ion are factors that can be used to 
detect the mass of the ion. [22] The detector produces a mass spectrum from this information, 
although the low number of ions leaving the mass analyzer at any given time makes signal 
amplification necessary.[22] An electron multiplier is a common detector, multiplying the 
incident charges several times over by a process called secondary emission, before measuring 
the electric charge with a metal anode[16]. Other commonly used detectors include Faraday 















Lithiation of imidazole is a common way to make C-C bonds on the 2-position of 1-
methylimidazole (1). High yields were reported by Torregrosa, et al., [23] when lithium 
powder was combined with different ketones to yield the corresponding alcohols. Although 
powdered lithium was used in the literature, the reaction was done using n-BuLi. The reaction 
is quenched with water, so total conversion of starting material can be challenging because of 
trace amounts of water. By exchanging the hydrogen with lithium, a strong nucleophile is 
created, which can easily link the central carbon to the electron-poor carbonyl. The resulting 
crude product was dried overnight. Because of its high polarity, purification by column was 
not optimal, and several combinations of ethyl acetate and n-pentane was attempted for 
crystallization. A 50/50 relationship was found to be optimal. 
 
 
Scheme 1: General procedure for lithiation of methylimidazole 
 
 
The reaction gave a 60% yield when executed as shown in scheme 2, and was shown to be 









Encouraged by the good yields of the lithiation, several nitration methods were attempted on 
the compound. Nitrations that could be done at lower temperatures were prioritized, as high 
temperatures combined with strong acids could eliminate the hydroxyl group.[24] However, if 
the elimination proved to give a high yield, a Markovnikov addition to reinsert the hydroxyl 
group was believed to be possible. 
 
6.2.1 Nitric acid in TFAA 
The first attempted method was reported by Katritzky, et al[25]. By cooling trifluoroacetic 
anhydride, adding the compound slowly, then adding nitric acid, high yields of nitrated 




Scheme 3: Nitration using nitric acid and TFAA 
 
As with all other nitration of imidazole where the nitrogen is substituted, two isomers would 
be expected. Because of steric hindrance, a higher yield of nitration on the 4 position was 
expected. The two isomers would have slightly different polarity, which would be favorable 
both for purification and determination of the desired product from the LCMS.  The reaction 
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initially was set for 12 h, and checked every hour. No product could be seen in the LCMS, 
although the starting material was being converted to an unknown product. A set of peaks 
with a mass larger than the starting material, but lower than the target molecules, was seen. 
The peak corresponding to the mass of the hydroxyl eliminated compound also was not 
shown. Because the heterocycle is aromatic, the chances of it tearing it open are low. The 
cyclobutane, however, is not aromatic, and, because of ring strain, there is a chance that it will 
be torn apart with possible the addition of nitro groups. Interactions between the hydroxyl 
group and the TFAA also are possible. 
 
6.2.2 t-BuONO 
The second method of nitration was attempted using t-BuONO in THF. t-BuONO has a wide 
range of uses and, as Maity, et al., reported in 2013, successful nitration of olefins[26]. 
Previous work done by the research group at LDDN also achieved success in nitrating 
aromatic complexes. The nitration is quick and easy to work up and makes for an efficient 




Scheme 4: Nitration using t-BuONO 
 
A drastic color change was observed in the reaction, indicating that something happened to 
the starting material. When the reaction was checked in the LCMS, however, no trace of 
product was found. As previously mentioned, t-BuONO had a wide range of uses, and it is 
difficult to estimate what could have happened; however, the chances of interactions between 
the hydroxyl group and the t-BuONO are high. Earlier success with nitration of aromatic 
complexes also have been executed using rings with more electron withdrawing substituents. 
After the initial 20 minutes, the reaction was left for 6 hours, while being checked every hour. 




6.2.3 Nitric acid and sulfuric acid 
The classic way of nitrating imidazole is to use sulfuric acid and nitric acid, without any 
solvent, under high temperature (60-80 degrees). Although such temperature was thought to 
remove the hydroxyl group, the reaction was attempted.  The reaction was done according to 
the synthesis performed by Morais, et al. [27] 
 
 
Scheme 5: Nitration using nitric acid and sulfuric acid 
 
One equivalent of nitric acid was added to one equivalent of sulfuric acid, before being cooled 
to 0OC using an ice bath. The compound was added slowly and left to stir for 45 min in the ice 
bath. The reaction then was heated to 60OC and left to stir for 6 hours. To see the 
development of the reaction, it was checked every hour using LCMS. A steady decrease of the 
starting material was observed. However, no trace of product was seen, and there was no sign 
of the eliminated molecule. Several very high and very small peaks were seen, indicating that 
the molecule was torn apart by the temperature. 
 
Although discouraged by this result, the same reaction was done at different temperatures to 









Table 1: Achieved results from nitration and different temperatures 
Temperature SM after 6h in 
LCMS 
Peaks of interest in LCMS 
0 OC No conversion Only starting material 
rt Partly converted Two peaks matching product 
40 OC Partly converted No peaks matching product 
60 OC Full conversion No peaks matching product 
 
 
When the reaction was done without any kind of heating or cooling, two peaks matching the 
product could be observed. One peak was larger than the other, corresponding to the expected 
isomer relationship. The product proved difficult to purify by column chromatography and 
could not be isolated. When the reaction was repeated on a 1g scale, no trace of product was 
seen. 
 
6.2.4 Ammonium nitrate and TFAA 
1-(1-methyl-1H-imidazol-2-yl)cyclobutan-1-ol (2) was dissolved in DCM and cooled to 0OC, 
before a stirred mixture of trifluoroacetic anhydride and NH4NO3 was added, according to the 




Scheme 6: Nitration using ammonium nitrate and TFAA 
 
The reaction was checked after 4 hours, with mostly starting material being present. No sign 
of product was seen. The nitration technique was used on a benzene ring in the literature, and 
18 
 
several alternative routes of reaction could be happening. As before, the chances of interaction 
between the ammonium nitrate, the hydroxyl group and the strained ring are high. The 
reaction then was left overnight with equal results when checked in the morning. 
 
6.2.5 Nitronium tetrafluoroborate 
In another effort to nitrate 1-(1-methyl-1H-imidazol-2-yl)cyclobutan-1-ol (2), nitronium 
tetrafluoroborate was used in accordance with Oláh, et al. [29] Using DMSO as a solvent, 
NO2BF4 was added to the compound at 0
OC. When extracted with ether after 12 h, the 









Having little success nitrating compound 2, several routes were attempted starting with the 
nitro group already attached to the imidazole. Starting with methylation of 4(5)-
nitroimidazole (4), several solvents and bases were used to try to methylate with highest 
possible yield.  Because of the high polarity of the starting material, only a selected set of 
solvents were usable. Compounds are traditionally methylated using methylhalide in research. 
Iodomethane was, therefore, used in combination with K2CO3 in accordance with Hao, et al. 





Scheme 8: Methylation of 4(5)-nitroimidazole (4) 
 
When the reaction was checked after 16 hours, no starting material was left and only the 
product was seen. As mentioned earlier, imidazole has two tautomeric forms, which makes 
the methylation able to happen on both nitrogen atoms. This resulted in the chromatogram 
showing two peaks with equal mass, one larger than the other. 
 
 
Chart 4: Isomers present in the reaction mixture after methylation of 4(5)-
nitroimidazole (4) 
 
As two isomers can have widely different abilities, they were attempted separated using 
column chromatography. Using DCM-MeOH, the peaks eluded nearly at the same time. Since 
the separation was not efficient, crystallization was attempted. The literature [30] reported 
success using 2-propanol, and when tried gave 70% yield of pure 1-methyl-4-nitro-1H-
















Scheme 9: Lithiaton of 1-methyl-4-nitro-1H-imidazol (5) 
 
In an attempt to attach the cyclobutanol to the ring, 1-methyl-4-nitro-1H-imidazol (5) was 
dissolved in THF, under an inert atmosphere before n-BuLi was added, while the reaction was 
cooled to -78oC. The ketone was added after 45 min and left to stir for another 45 min. The 
reaction was quenched using water. A color change occurred when the lithium was added, 
indicating that a reaction was happening. When worked up, the LCMS showed a huge range 
of peaks from 80 m/z to 400 m/z. No starting material was left, and no sign of product was 
seen. Because of the lack of starting material, the lithium seems to have attached, but the 
complex might have been too unstable to attach the ketone. 
 
To see if the reaction would work if the ketone was present during the lithiation, the reaction 
was repeated; this time, however, the ketone was added first, while the lithium was added 










Scheme 10: Lithiation of 1-methyl-4-nitro-1H-imidazol using Sec-BuLi 
 
Although lithiation was suspected to have occurred, the reaction was executed using the same 
conditions using sec-BuLi to see if the results varied. Sec-BuLi, being a more reactive 
lithiation agent, could be useful if the hydrogen was difficult to remove. The reaction, 
however, yielded the same results. 
 
The instability of the lithiated complex most likely appears because of the electron-





When the addition of cyclobutanol to 1-methyl-4-nitro-1H-imidazol failed, reducing the nitro 
group to an amine, and thereafter protecting it, seemed like a promising route. An 
overwhelming amount of reactions leading to natural products include at least one 
hydrogenation step, with several well-documented routes utilizing transition metals.[31] With 
the constant need for effective reductions, many elegant reactions have been developed. 
Several of them rely on hydrogen donors, like 1,4-cylohexadiene and ammonium formate. 
Since these substances are solids or liquids, selective hydrogenation is possible by controlling 
the equivalents. Despite its uses, these reactions often require high temperatures, and often 




The most common method is to use palladium on carbon in combination with hydrogen gas. 
Despite the inherit danger of using hydrogen gas, the mild conditions in which this reaction 
can take place makes the reaction possible without any further need for purification. Pd/C is 
the universal reagent for this hydrogenation, but, because of its ability to create sparks when 
mixed with the solvent, Pd(OH)2/C was favored.[30] 
 
 
Scheme 11: Reduction of 1-methyl-4-nitro-1H-imidazol (5) 
 
Pd(OH)2/C was mixed with of 1-methyl-4-nitro-1H-imidazol (5) and ethanol before the flask 
was flushed with argon, and then hydrogen. The reaction was left overnight and checked 
using LCMS in the morning. It showed full conversion into the target molecule. 
 
 
Figure 7: MS of 1-methyl-1H-imidazol-4-amine (6) 
 
When an 1H-NMR was taken of the molecule, however, the spectra seemed to show more 
peaks than expected. A TLC was done and showed that several substances were present. 
When the flask was left overnight, the color of the mixture darkened drastically, indicating 
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that something was happening. Another TLC was done, showing many more spots, and less of 
the relevant amine. When tested using LCMS at this point, it still only showed compound 6. 
The reaction was repeated and checked every 20 min for 2 hours until the reaction was 
completed. The reaction was worked up immediately when done, yielding a clear substance 
with only a hint of yellow. An 1H-NMR was taken again, showing pure product. When the 
pure product was left, it again darkened, showing that action was necessary to prevent the 
deterioration. Amines, especially when small, have a habit of polymerizing, which also could 
be the case here.[33] The thick, tar-like substance that was created could explain the pure 
LCMS, as the tar would not go through the column. Light, air, and temperature all could be 
factors catalyzing this. Three small batches were made, and then were stored, respectively, in 
darkness, under vacuum, and in the freezer. Only the one in the freezer had its lifetime 
extended. 
 
Because of concerns regarding further reactions needing higher temperature and long reaction 
times, keeping the compound cool at all times seemed difficult, and the literature was 
consulted. Su, et al., [34] documented success by creating an HCl salt out of the amine, using 
ethanol saturated with HCl, with a yield as high as 100%. When this reaction was repeated, 
however, only a 20% yield could be accomplished, despite using as much as five equivalents 
of HCl. When the remaining liquid after the HCl addition was tested using 1H-NMR, it was 
still pure product that remained. This made it necessary to synthesize the amine immediately 
before the next reactions. 
 








A wide range of protective groups are available for amines. They have become increasingly 
important because of the rising need for peptide synthesis.[35] Acylation, sulfonation and 
alkylation are all possible routes for protection, depending on further reaction conditions. 
Together with fluorenylmethyloxycarbonyl (Fmoc), di-tert-butyl dicarbonate (BOC) are the 
most common. Since the next step would be a lithiation, BOC was found to be suitable, as it 
is resistant to both the nucleophilic effects of the n-BuLi, and its base abilities.[35] 
 
 
Figure 8: BOC group 
 
Despite low solubility, DCM was chosen as solvent. The compound was mixed with the 
DCM, and 1.1 equivalents of BOC were added and stirred for 2 hours. No more starting 
material was visible in the LCMS, and the reaction mixture was columned using 
DCM:MeOH. Although the molecule was worked up in pure form, the reaction only gave a 
17% yield. In an attempt to improve this yield, DMF and DCM were tried as solvents in 
combination with different bases. The DMF also was heated. Because of DCM’s low boiling 
point, no heating was attempted with it. The diminishing amount of starting material 
displayed in the LCMS showed that a reaction was happening, and no more equivalents of 










Table 2: DMF and DCM as solvent for BOC group 
Experiment Solvent Base Temperature 
(OC) 
Yield 
1 DMF TEA RT 19% 
2 DMF TEA 40 23% 
3 DMF TEA 60 14% 
4 DMF TEA 80 6% 
5 DMF Cs2CO3 RT 12% 
6 DMF Cs2CO3 40 6% 
7 DMF Cs2CO3 60 No product 
8 DMF Cs2CO3 80 No product 
9 DCM TEA RT 17% 
10 DCM Cs2CO3 RT 15% 
 
Despite the low yield of the reaction, a lithiation was attempted. 
 
6.7 tert-butyl (2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazol-4-yl)carbamate 
 
 
Scheme 13: Addition of cyclobutanol to tert-butyl (1-methyl-1H-imidazol-4-
yl)carbamate 
 
The reaction was executed in the same fashion as earlier, letting the n-BuLi stir for 45 minutes 
before the ketone was added. When worked up, it gave the target compound in a 15% yield. 
While the central hydrogen is the common spot for lithiations on imidazole, substituents may 
change this.  The carbamate is ortho-directing, and hence there was a chance that the ketone 
could attach there. The two hydrogen atoms on imidazole are very close in the 1H-NMR, and 
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the ketone was thought to attach in the right position. Despite this, because the use of a 
protective group would turn the final number of steps to six, the low yield of the BOC 





Scheme 14: Benzyl protection of 1-methyl-1H-imidazol-4-amine (6) 
 
 
Using benzyl bromide is a common way of protecting amines and alcohol [35]. It is easily 
removed using H2 gas and Pd/C. Because of the two nitrogen atoms in the imidazole, the 
hydrogen in the 2-poisition is more easily removed than any of the phenyl hydrogen atoms, 
and the benzyl group poses no risk for lithiation. With this in mind, the amine was dissolved 
in DCM and 2 equivalents of TEA was added. 1.1 equivalents of bromobenzyl then was 
added, and the reaction was left to stir over night. When the reaction was checked using 
LCMS, no sign of product could be found, with substantial amounts of side product visible. 
No starting material could be seen. The reaction was, therefore, repeated, and a tiny peak 
could be seen corresponding to the target molecule after half an hour. The reaction mixture 
attempted purified using flash chromatography, but no trace of product was seen. This lack of 
product is puzzling, as it ideally would be a simple sn2 reaction. No trace of the bis protected 








Jung, et al., reported, in 2002, optimized results of amine protection, using formic acid to 
form an amide[36]. He reported a staggering 99% yield. Acetic acid was, therefore, cooled to 
0OC, and formic acid was added slowly. The solution was stirred for 20 mins before a solution 
of starting material mixed in DMF was added slowly and stirred at room temperature for an 
hour. The reaction then was quenched using base and purified by trituration with cyclohexane.  
 
 
Scheme 15: Amide protection of 1-methyl-1H-imidazol-4-amine (6) 
 
The reaction gave a yield of 30%, which was lower than expected, but it would be sufficient 
for the six-step reaction. The next step would, hence, be to lithiate. Because the amide proved 
difficult to dissolve in THF, alternative dry solvents were explored. This was, however, futile, 
as dry DMC and dry diethyl ether also failed to dissolve it. Dry THF was, therefore, selected, 
in hopes that the solubility would increase when the reaction started. When the lithiation was 
done, it became clear that not enough of the compound has dissolved, and, although clearly 
visible in the LCMS, only 7% of starting material was converted to product. Lacking a proper 




Amines can be converted easily into amides using carboxyl acids, as previously shown using 
formic acid, or by using acid derivatives. [37] The downside of using carboxylic acids is that 
it needs to be activated due to the hydroxyl groups poor leaving group abilities.[37] This is 





Scheme 16: Amide bond creation from carboxylic acid and amine 
 
By using an acid chloride, the need for DCC as an activating reagent is gone, and the reaction 
can be done using a simple base, such as TEA or K2CO3. [38] 
 
 
Scheme 17: Reaction mechanism when an acid chloride is used 
 
The amine (6) was dissolved in DCM and two equivalents of TEA was added, before the acid 
chloride was added to the reaction mixture. After ten minutes, the reaction was tested using 
LCMS, and a substantial peak for the product was seen with little else present. The reaction 
mixture was washed three times with water before the organic phase was purified using flash 
chromatography to yield the amide in a 75% yield. The quick reaction time might correlate to 
the high yield, as previous reactions done to the amine often needed more than 8 hours to 
achieve results. This could indicate that the unreacted amine in earlier reactions, such as the 










Scheme 19: Lithiaton of 3-chloro-4-fluoro-N-(1-methyl-1H-imidazol-4-yl)-benzamide 
(11) 
 
With five different aromatic hydrogen atoms present in the two aromatic rings, the benzamide 
poses many opportunities for the lithium to attach. However, coordination of the lithium is 
determined by the already present substituents. On the phenyl ring, all groups are 
deactivating, making it difficult for the lithium to replace the hydrogen. [24] In figure 9, each 






Figure 9: Deactivating effects on the phenyl ring 
 
On the heterocyclic ring, the amide activates the backbone.[24] With the 2-position being the 
naturally easier part to remove hydrogen, it was uncertain were the lithiation would find 
place. The 3-chloro-4-fluoro-N-(1-methyl-1H-imidazol-4-yl)-benzamide (11) was dissolved 
in dry THF in a flask flushed with argon, before n-BuLi was added at -78OC. The reaction 
mixture was left to stir for 45 minutes before the ketone was added. It was left to stir for 
another 45 minutes before being quenched with water. The reaction mixture was analyzed 
using LCMS, showing a mass corresponding to the target molecule. 
 
The water phase was extracted with ethyl acetate and purified using column chromatography. 
An 1H-NMR was done of the compound, revealing that the ketone had added to the imidazole. 
However, because of the proximity of the two peaks corresponding to the hydrogen atoms, 
identifying where the group had attached was an issue. A COSY and a NOESY spectrum was 
done, without being able to determine it. Since access to crystallography was possible, 
crystals were attempted grown from the product. Crystals can be challenging to grow, and 
could take anywhere between two weeks to a year; after a month of no success, other ways of 
analyzing it were considered. [39] The synthesis was repeated to gain 25 mg of the product, 
enough to do an HMBC analysis. To compare, an HMBC also was done of 3-chloro-4-fluoro-





Figure 10: HMBC of 3-chloro-4-fluoro-N-(1-methyl-1H-imidazol-4-yl)-benzamide (11) 
 
 







Chart 5: The two possible outcomes of the lithiation 
 
In the HMBC for the final product, the amide hydrogen, shown to the far left, links to two 
carbon atoms. The bottom one is the carbonyl, and the top one is the tertiary imidazole 
carbon. This carbon again links to the hydroxyl group. This could not be possible if the 
cyclobutanol had attached in the two position. The only possible conclusion is that it attached 




With the attachment of the cyclobutanol group on the backbone in mind, it was necessary to 
direct cyclobutanol addition by other means. This could be done either by using protective 
groups that did not form amides, or by making the hydrogen in the 2-position a more lucrative 
spot for the lithiation. Lithiation can be done in several ways, and replacing hydrogen as it has 
been so far, is a common way. It is, however, also possible to exchange a bromide.[40] Since 
this reaction has another mechanism than dehydrogenation, it offers a chance of attaching the 
cyclobutanol where dehydrogenation has failed. The target molecule’s biggest challenge is 
attaching the nitro group and the cyclobutanol group at the same time, and by attaching a 
bromide to the 4-nitroimidazole, an exchange of bromide with lithium could be possible at 
any step in the synthesis. This also opens the possibility of using a Grignard reagent. 
 
Using 4-nitroimidazole (5) as starting material, there is a wide range of bromination 
techniques available. Halogenation of organic compounds happens trough free radical 
halogenation, ketone halogenation, electrophilic halogenation, or halogen addition 
reactions.[41] N-bromo succinimide (NBS) is one of the most applied way of brominating, as 
it can be done under mild conditions, without the need for toxic reagents.[42] Using 
acetonitrile as solvent, 1 equivalent of NBS was added to the solvent together with the starting 
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Following the procedure of Pedada et al [43], bromination of both the backbone and the 2-
position before selective debromination was necessary, as no viable route using 4-
nitroimidazole as starting material with selective bromination could be established. The 
author stressed the need for slow addition, as dense CO2 clouds form, presumably from 
reaction between sodium bicarbonate and hydrogen bromide formed during the reaction. 
Because of the aromatic complex, harsh conditions were necessary.  
 
 
Scheme 21: Debromination of 4-nitroimidazole (5) 
 
Sodium bicarbonate was added to water, together with the starting material. The reaction was 
cooled to 0OC before the bromide was slowly added dropwise. The reaction was left to stir for 
an hour before it was heated to 65 OC, and was left to stir for 3 hours. Because of the drastic 
change in the molecule’s polarity, it precipitated as a fine yellow powder that was easily 





Pedada, et al., also reported optimizing the debromination[43]. By using potassium iodide and 
sodium sulfate in acetic acid, bromide was removed from the backbone in an 81% yield. By 
quenching the reaction with sodium metasulfite and water, and then extracting with ethyl 
acetate, no further purification was necessary. 
 






Since little success with the BuLi reactions to nitromidazole was gained previously, the 
activation of the 2-position through halogen addition could offer new possibilities, as the 




Equation 2: Lithium halogen exchange[40] 
 
The compound was lithiated using THF as solvent. The reaction was immediately colored 
black, a characteristic that also could be observed with the 1-methyl-4-nitro-1H-imidazol (5). 
The reaction was checked using LCMS 20 minutes and 40 minutes after the addition of 
cyclobutanone. Like previous attempts, this too showed a wide range of peaks, hinting that the 
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lithium had attached, but remained unstable. The reaction was, therefore, repeated adding the 




Scheme 23: Lithiation of 2-bromo-1-methyl-4-nitro-1H-imidazole (13) 
 
6.15.2 Grignard 
Lithium is only one of many metals used for carbon-carbon coupling reaction. A common 
alternative is the use of magnesium in combination with a halogen.[44] This creates a 
Grignard reagent, which, in turn, can create six-membered ring transition state, by the 
Grignard functioning as a nucleophile, attacking the electrophilic carbon that is present within 
the polar bond of a carbonyl group.[44] The only drawback of the reaction is, like lithiations, 




Scheme 24: Grignard reaction 
 
The reaction will run by itself if enough activation energy is given. A heat gun was used, 
which made the characteristic iodine color quickly clear up. The reaction was checked using 
LCMS every 15 minutes for 45 minutes. A steady conversion of the starting material to a set 




The presence of the nitro group on the aromatic ring might be the cause of this. The use of 
nitroarene, in combination with Grignard reagents, has been extensively studied, and hints 
that the compounds might be creating carbon-nitrogen bonds with itself. Bartoli, et al., [45]  




Scheme 25: Suggested addition for aromatic Grignard reagents by Bartoli et al[45] 
 
Since 2-bromo-1-methyl-4-nitro-1H-imidazole (13) is not only the Grignard reagent, but also 





Having little success coupling the ketone to the 2-position, it was theorized that changing the 
nitro group could be advantageous. By reducing it and then creating an amide, a lithiation 
could be repeated when the electron withdrawing abilities were changed. As previously 
mentioned, a wide range of syntheses include at least one reduction, with Palladium on carbon 
being the catalyst of choice, because of the easy work up and pure conversion. With the 
bromide in the 2-position, this, however, becomes difficult. A Buchwald reaction uses 
palladium to easily cleave off bromide from aromatic complexes[46]. Despite this, the 






Scheme 26: Reduction of 2-bromo-1-methyl-4-nitro-1H-imidazole (13) 
 
The reaction was set up and checked using LCMS every 10 minutes. Over 1 hour, the starting 
material was converted into the debrominated compound. A small peak corresponding to a 
reduced and debrominated compound also was visible. After two hours, only the reduced and 
debrominated compound was left, with no starting material. 
 
6.16.2 Iron 
To bypass the need for palladium, alternative reduction techniques were considered. Using 
iron with an acid catalyst is a non-toxic way that has proven to reduce efficiently [47]. This 
also removes the need for hydrogen gas. The reaction is messy, however, and often requires 
harsher conditions. 
 
Using acetic acid as a catalyst 2-bromo-1-methyl-4-nitro-1H-imidazole (13) was dissolved in 








The reaction was checked every 30 minutes for 8 hours. A very slow conversion of starting 
material took place. The peaks produced did not correspond to anything predictable. Only a 
small percentage of the starting material had been converted though, and the temperature was 
increased to 70OC. The reaction was left for 2 hours ,and the same trend was seen, with the 
starting material converted at a much quicker rate, but still no peak corresponding to the 
product visible. 
 
6.17 methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-4-carboxylate 
 
Seeing the potential of using a group on the backbone of imidazole to direct the 
cyclobutanone, before converting said group to the required amide, methyl 1-methyl-1H-




Scheme 28: Lithiation of 1-methyl-1H-imidazole-4-carboxylate (16) 
 
The reaction was executed in the same way as with 1-methyl-4-nitro-1H-imidazol (5). 
However, when the reaction was checked 20 minutes and 40 minutes after the ketone had 
been added, no product was visible. The reaction was, therefore, repeated, adding the ketone 
first, before the n-BuLi was added. Although a very small peak corresponding to product 






7 Results from testing 
 
Compound 11 and 12 were sent to Indiana University School of Medicine and tested in 
accordance with the luciferase reporter assay described earlier. Details for the assay are listed 
in the appendix. The two compounds were tested twice, with results expressed in luciferase 





Chart 6: First run, compound 11 to the left, 12 to the right 
 
Chart 7: Second run, compound 11 to the left, 12 to the right 
 
The two runs gave matching results, with compound 11 yielding some slight activity at the 











The main aim of this project was to synthesize analogs of the previously optimized lead 
compounds 4m and 27 that had proven to extend the life of the SMN protein. A molecule that 
previously used heterocycle thiazole was exchanged with imidazole was envisioned. The 
exchange was thought to increase activity and solubility. 
 
 
Figure 12: Target Molecule 
 
1-(1-Methyl-1H-imidazol-2-yl)cyclobutan-1-ol (2) was synthesized in good yields by 
lithiation of 1-methylimidazole following the method suggested by Torregrosa and co 
workers[23]. 1-(1-methyl-1H-imidazol-2-yl)cyclobutan-1-ol (3) then was attempted to be 
nitrated using five different methods. Nitration using trifluoroacetic anhydride and nitric acid 
following the method given by Katritzky, et al. [25], lead to a slow deterioration of 2. Peaks 
in the LCMS did not correspond to anything predictable. t-BuONO in THF was attempted and 
gave the same results. The electron withdrawing effects of the ring might be the cause of the 
wide range of peaks observed in the LCMS. When nitric acid and sulfuric acid were used[27], 
no product could be seen when the reaction was heated to 60OC, which hinted that the 
conditions were too harsh. The reaction was repeated using different temperatures, and, when 
room temperature was applied, the reaction showed promising peaks in the LCMS. Two 
peaks, one higher than the other, were observed, which could correspond to the expected 
isomers. The product, however, could not be isolated. When the reaction was repeated on 
larger scale, the lack of applied energy gave a disappointing lack of expected product. As an 
alternative way of nitration, a technique reported by Mazgarova, et al.,[28] was attempted, 
using ammonium nitrate and trifluoroacetic anhydride. Compound 2 was converted, but no 
product could be seen to develop. As before, the mildly strained cyclobutane ring and the 
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hydroxyl group were thought to be interacting with the reagent.  A nitration technique in 
accordance with Oláh and coworkers [29] was attempted, using nitronium tetrafluoroborate in 
DMSO at 0OC. No product was seen, despite conversion of starting material. 
 
Attempting a different route, 4(5)-nitroimidazole (4) was methylated in good yield using 
iodomethane and K2CO3 in accordance with Hao, et al.[30] To separate the isomers, the 
product was recrystallized from 2-propanol. Compound 5 was attempted to be lithiated using 
both n-BuLi and sec-BuLi. Both experiments showed a wide range of peaks in the LCMS. 
Since the starting material was converted, the aromatic ring was thought to have been lithiated 
successfully. The resulting complex, however, is suspected of being unstable and unable to 
attach the cyclobutanol ring. The same result was seen when the ketone was added before the 
lithium. 
 
Compound 5 was reduced using Pd(OH)2/C. The starting material easily was converted to 
product over 2 h. However, the resulting compound deteriorated after isolation, and is thought 
to have polymerized. To combat this, HCl was added to try to make a salt of the molecule. 
This gave poor yield, and the amine (6) was, therefore, made in situ, before any further steps 
thereafter. Several protective groups were attempted. BOC was attached successfully, but 
without sufficient yield, despite optimization. Despite this, a lithiation was attempted 
successfully. Because of the low yield, the route was abandoned.  Benzyl bromide was also 
attempted, but the product was only barely visible in the LCMS. No product could be 
purified. Using formic acid, an amide protected amine was created successfully in sufficient 
yield. The product had severe problems dissolving in THF, and the lithiation in the next step 
gave too low yield for further use. Since the amine (6) gave such low yields with the 
protective groups, direct amidation leading to 3-chloro-4-fluoro-N-(1-methyl-1H-imidazol-4-
yl)-benzamide (11) using an acid chloride was performed in a 75% yield. The deactivating 
effects of the phenyl group was rightfully thought to make it difficult for lithium to attach 
there, and the imidazole ring was, therefore, successfully lithiated. The ketone did, however, 
attach on the backbone of the imidazole, leading to the analog 3-chloro-4-fluoro-N-(5-(1-
hydroxycyclobutyl)-1-methyl-1H-imidazol-4-yl)benzamide (12) of the target molecule in a 
31.31% yield. This analog, together with the previous amide, were sent for testing. 
42 
 
Envisioning a route where a bromide could be used to direct the lithiation, Compound 5 was 
attempted brominated using NBS. No starting material was converted, and the need for 
harsher conditions was clear. Bromine was, therefore, used, leading to 2,5-dibromo-1-methyl-
4-nitro-1H-imidazole (14) in a 49.61 yield. The compound was easily worked up and 
dibrominated, using potassium iodide and sodium sulfite in acetic acid, giving 2-bromo-1-
methyl-4-nitro-1H-imidazole (13) in a 81% yield.. A Grignard reaction was attempted, 
resulting in large molecules that correspond to reactions involving the nitro group. Lithiation 
of compound 13 gave the same kind of results that the dehydrogenation had given. Compound 
13 was, therefore, attempted to be reduced. An attempt at using Pd(OH)2/C clearly favored 
debromination before reduction, resulting in no product. Reduction using iron also was 
attempted, and, despite the gradual conversion of starting material, no product was created. 
 
In an attempt at using an ester on the backbone of imidazole to direct the lithium, methyl 1-
methyl-1H-imidazole-4-carboxylate (16) was attempted lithiated. No product could be seen in 
the LCMS, and the reaction was therefore repeated adding the ketone before the n-BuLi. 
Although a peak corresponding to the mass could be observed, purification yielded no 
product. 
 
8.2 Future Work 
 
As the various compounds previously synthesized within the SMA project have proven to 
give substantial effect, further work should focus on the continued attempt at synthesizing the 
target molecule that was not achieved in this project. A wide range of less common protective 
groups can be used to protect compound 6 where both the yield of the protected amine and the 
directional effects for the lithiation are important.[35] The possibility of creating the 
imidazole ring with substituents already attached remains an option.[49] The nitration of 1-(1-
methyl-1H-imidazol-2-yl)cyclobutan-1-ol (2) using sulfuric acid and nitric acid gave 
promising results, and, with more time, could possibly be optimized to give a decent yield. 
 
The activity of substituents can drastically alter the effect of the target molecule. Creating a 
short synthesis path, where a wide range of substituents can be used, would make for a huge 
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range of analogs that could not only yield answers regarding the activity of the substituents, 
but also the potency of imidazole. 
 
As the synthesis of organic compounds for Spinal Muscular Atrophy continues to be a 
promising route of treatment, further work should center around the continued optimization of 
the current lead compounds. Other heterocycles such as 1,3-dioxolane and sulfolane remain 
options. In addition, furthering our understanding of the mechanism behind the drug would 






























All chemicals were purchased commercially and used as received. 
 
9.2 Experimental Description 
 
TLC analyses were performed on coated aluminum foil and coated glass. In most cases a 
mobile phase consisting of various mixtures of either hexane and ethyl acetate, or 
dichloromethane and methanol were used. 
Manual flash chromatography was performed using a stationary phase of silica gel (60 F254). 
The automated silica column flash chromatography was carried out on an 60H silica gel 
(Merck 9385) 
 
9.3 Spectroscopic and Spectrometric Descriptions 
 
NMR spectra were obtained on a Bruker Biospin AV500, 500 Hz. Chemical shifts are 
reported in ppm relative to the signal of the remaining protons of the deuterated solvent used. 
Coupling constants are given in Hz and the multiplicity is reported as singlet (s), doublet (d), 
triplet (t), quartet (qt) and multiplet (m). 
 
LC-MS analysis were performed on an Agilent 6420A triplet quadropole (QqQ configuariton) 
mass analyzer using electrospray ionization (ESI). It is connected to an Agilent 1200 series 
LC module (binary pump, column compartment/oven and autosampler). The column was an 








A 50 mL round bottom flask charged with 1-methylimidazole (1.94 mL, 24.36 mmol) was 
flushed with argon before anhydrous THF (40 mL) was added. The reaction was mixture 
cooled to -78OC, before n-BuLi (19.50 mL, 2.5 M) was added dropwise over 15 minutes and 
left to stir for 45 minutes. Cyclobutanone (1.97 mL, 26.96 mmol) was transferred to the flask 
and the reaction mixture was left to stir for another 45 minutes. The solution was then 
quenched with water (20 mL), and the water phase was extracted with ethyl acetate (3 x 20 
mL). The extract was concentrated down to give a yellow powder. This solid was purified by 
crystallized from ethyl acetate and pentane (50/50) to yield the product as white crystals (2.24 




Nitric acid and TFAA 
A 25 mL round bottom flask was charged with trifluoroacetic anhydride (1 mL), before being 
chilled in an ice bath. 1-(1-methyl-1H-imidazol-2-yl)cyclobutan-1-ol (0.26 g, 1.7 mmol) was 
transferred to the flask slowly. After 1 h under constant stirring, concentrated nitric acid (0.3 
mL, 4.89 mmol) was added dropwise. After stirring for 12 h at room temperature, the excess 





A 25 mL round bottom flask was charged with 1-(1-methyl-1H-imidazol-2-yl)cyclobutan-1-ol 
(0.26 g, 1.7 mmol) solved in THF (2 mL), before t-buONO (0.35 g, 3.44 mmol) was added 





Nitric acid and sulfuric acid 
A 25 mL round bottom flask was charged with sulfuric acid (0.036 mL) and concentrated 
nitric acid (0.040 mL, 0.65 mmol) and cooled to 0OC. After 1 h of constant stirring, 1-(1-
methyl-1H-imidazol-2-yl)cyclobutan-1-ol (0.10 g, 0.65 mmol) was added slowly. The 
reaction was then heated to 60 OC and left to stir for 6 h. Sodium bicarbonate in water was 
used to quench the reaction, and the water phase was extracted with ethyl acetate (3 x 5 mL). 
The organic phase was removed under vacuum to give a yellow powder. The powder was 
attempted purified using column chromatography (0-10 MeOH/DCM) but no product was 
yielded. 
 
Ammonium nitrate and TFAA 
A 25 mL round bottom flask was charged with 1-(1-methyl-1H-imidazol-2-yl)cyclobutan-1-ol 
(0.10 g, 0.65 mmol) dissolved in DCM (5 mL) and cooled to 0OC. A stirred mixture of 
ammonium nitrate (0.26 g, 3.19 mmol) and trifluoroacetic anhydride (1.87 mL, 13.2 mmol) 
was transferred, and the reaction was left to stir while reaching room temperature. After 18 h, 
the reaction was poured in to ice and extracted with DCM (3 x 10 mL). No product was 
yielded from the reaction. 
 
Nitronium Tetrafluoroborate 
A 25 mL round bottom flask was flushed with argon before it was charged with 1-(1-methyl-
1H-imidazol-2-yl)cyclobutan-1-ol (0.10 g, 0.66 mmol) and DMSO (5 mL). The mixture was 
cooled, and a solution of  nitronium tetrafluoroborate (0.18 mL, 0.5 M) was added dropwise. 
The reaction mixture was left to stir for 12 h, before it was extracted with diethyl ether (3 x 10 




A 250 mL round bottom flask was charged with 4-Nitro-1H-imidazol (3.30 g, 29.19 mmol) 
and acetonitrile (60 mL). Potassium carbonate (6.60 g, 47.75 mmol) and iodomethane (2.45 
mL, 39.18 mmol) were transferred. The reaction mixture was heated at 65 °C and left 
overnight. The mixture was then filtered, and the filtrate was concentrated in vacuo, leaving 
an orange solid. This solid was columned (0-10% MeOH/DCM). The resulting fractions were 
concentrated in vacuo to give 1-methyl-4(5)-nitro-1H-imidazol as an off-white solid. The 
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product was recrystallized from 2-propanol to yield 1-methyl-4-nitro-1H-imidazol as white 
crystals (2.57 g, 20.26 mmol, 70%). 1H NMR (DMSO-d6): δ = 8.33 (1H, s), 7.78 (1H, s), 3.73 





A 25 mL round bottom flask charged with 1-methyl-4-nitro-1H-imidazol (0.10 g, 0.79 mmol) 
was flushed with argon before anhydrous THF (5 mL) was added. The reaction was mixture 
cooled to -78OC, before n-BuLi (0.63 mL, 2.5 M) was added dropwise over 10 minutes and 
left to stir for 45 minutes. Cyclobutanone (0.06 mL, 0.87 mmol) was transferred to the flask 
and the reaction mixture was left to stir for another 45 minutes. The solution was then 
quenched with 5 mL water, and the water phase was extracted with ethyl acetate (3 x 10 mL). 




A 25 mL round bottom flask charged with 1-methyl-4-nitro-1H-imidazol (0.10 g, 0.79 mmol) 
was flushed with argon before anhydrous THF (5 mL) was added. The reaction was mixture 
cooled to -78OC, before sec-BuLi (0.63 mL, 2.5 M) was added dropwise over 10 minutes and 
left to stir for 45 minutes. Cyclobutanone (0.06 mL, 0.87 mmol) was transferred to the flask 
and the reaction mixture was left to stir for another 45 minutes. The solution was then 
quenched with 5 mL water, and the water phase was extracted with ethyl acetate (3 x 10 mL). 





A 50 mL round bottom flask was charged with 1-methyl-4-nitro-1H-imidazol (0.88 g, 6.89 
mmol) dissolved in ethanol (30 mL) together with Pd(OH)2/C (0.10 g). The mixture was 
subjected to an atmosphere of hydrogen for 3 h at room temperature. The mixture was filtered 
and the organic layer was concentrated to give 1-methyl-1H-imidazol-4-amine as a pale 
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yellow oil (0.664 g, 6.84 mmol, 99.24%). 1H NMR (DMSO-d6): δ = 8.39 (1H, s), 6.56 (1H, 
s), 4.78 (2H, s), 3.67 (3H, s) 
 
Tert-butyl (1-methyl-1H-imidazol-4-yl)carbamate (7) 
 
1-methyl-1H-imidazol-4-amine (0.10 g, 1.03 mmol) dissolved in DCM (10 mL) was added to 
a round 25 ml round bottom flask and TEA (0.29 mL, 2.06 mmol) was transferred. Di-tert-
butyl dicarbonate (0.25 g, 1.13 mmol) was added to the mixture, before it was left to stir. 
After 2 h, the reaction was washed with water (3 x 5 mL), before the organic layer was 
concentrated to give an orange powder. The powder was purified using column 
chromatography (0-10 MeOH/DCM). The fractions were concentrated in vacuo to give Tert-
butyl (1-methyl-1H-imidazol-4-yl)carbamate as a white powder (0.034 g, 0.175 mmol, 17%). 
 
tert-butyl (2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazol-4-yl)carbamate (8) 
 
A 25 mL round bottom flask charged with Tert-butyl (1-methyl-1H-imidazol-4-yl)carbamate 
(0.10 g, 0.50 mmol) was flushed with argon before anhydrous THF (5 mL) was added. The 
reaction was mixture cooled to -78OC, before n-BuLi (0.40 mL, 2.5 M) was added dropwise 
over 10 minutes and left to stir for 45 minutes. Cyclobutanone (0.038 mL, 0.55 mmol) was 
transferred to the flask and the reaction mixture was left to stir for another 45 minutes. The 
solution was then quenched with 5 mL water, and the water phase was extracted with ethyl 
acetate (3 x 10 mL). The extract was concentrated down to give a yellow powder. The powder 
was purified using column chromatography (0-10% MeOH/DCM). The fractions were 




A 25 mL round bottom flask was charged with 1-methyl-1H-imidazol-4-amine (0.10 g, 1.03 
mmol) dissolved in DCM (10 mL). TEA (0.29 mL, 2.06 mmol) was transferred, before benzyl 
bromide (0.13 mmol, 1.13 mmol) was added. The reaction was left to stir for 16 h, before the 
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reaction mixture was washed with water (3 x 5 mL). The organic layer was concentrated 




A 10 mL round bottom flask was charged with acetic acid (0.24 mL, 2.57 mmol) and cooled 
to 0OC. Formic was (0.27 mL, 7.20 mmol) was added dropwise and the reaction was stirred 
for 20 minutes, before a solution of 1-methyl-1H-imidazol-4-amine (0.20 g, 2.06 mmol) and 
DMF (1 mL) was added dropwise. The reaction was left to stir for 1 h at room temperature. 
Cyclohexane (2 mL) was added and the product precipitated as white powder. The powder 
was filtrated off and washed with cyclohexane to yield N-(1-methyl-1H-imidazol-4-
yl)formamide (0.08 g , 30%) as a white solid. 1H NMR (DMSO-d6): δ = 11.11 (1H, s), 8.62 




A 100 mL round bottom flask was charged with 1-methyl-1H-imidazol-4-amine (0.23 g, 2.36 
mmol) and DCM (50 mL) before TEA (0.66 mL, 4.69 mmol)  and 3-chloro-4-fluorobenzoyl 
chloride (0.50 g, 2.59 mmol) was added. The reaction mixture was stirred for 10 min before 
the organic phase was washed with water (3 x 20 mL). The organic phase was concentrated in 
vacuo, leaving behind a red powder. The solid was purified by column chromatography (0-5% 
MeOH/DCM). The resulting fractions were combined and concentrated in vacuo to yield the 
product as a brown powder (0.45 g, 1.77 mmol, 75.00%). 1H NMR (DMSO-d6): δ =10.89 





A flask charged with 3-chloro-4-fluoro-N-(1-methyl-1H-imidazol-4-yl)-benzamide (0.15 g, 
0.59 mmol) was flushed with argon before anhydrous THF (5 mL) was added. The reaction 
was cooled to -78OC, before n-BuLi (0.47 mL, 2.5M) was dropwise over 10 minutes and left 
to stir for 45 minutes. Cyclobutanone (0.05 mL, 0.65 mmol) was transferred to the flask and 
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the reaction mixture was left to stir for another 45 minutes. The reaction mixture was then 
quenched with 3 mL water, and the water phase was extracted with ethyl acetate (3 x 5 mL). 
The extract was concentrated in vacuo to give a yellow powder. The solid was purified using 
column chromatography (0-10 MeOH/DCM). The resulting fractions were combined and 
concentrated in vacuo to yield the product as a yellow powder (0.06 g, 0.19 mmol, 31.31% 
yield) 1H NMR (DMSO-d6): δ = 10.05 (1H, s), 8.12 (1H, s), 7.97 (1H, s), 7.56 (1H, s), 7.49 




A flask was charged with 1-methyl-4-nitro-1H-imidazol (0.100 g, 0.79 mmol) dissolved in 
acetonitrile (10 mL). NBS (0.140 g, 0.79 mmol) was added, and the reaction was left to stir 
for 12 h. Water (10 mL) was added and the water phase was extracted with ethyl acetate (3 x 




A 25 mL round bottom flask was charged with water (0.5 mL), sodium bicarbonate (0.152 g, 
1.81 mmol) and 1-methyl-4-nitro-1H-imidazol (0.10 g, 0.78 mmol). The solution was cooled 
to 0 OC and bromine (0.097 mL, 1.88 mmol) was added dropwise using a drop funnel. The 
reaction was left to stir for 1 h before being heated to 65OC. The reaction was left stirring for 
another 3 h. A white product precipitated from the solution. It was filtrated off and washed 
with water to yield the product (0.110g, 0.387 mmol, 49.61 % yield). 1H NMR (DMSO-d6): δ 




A 25 ml round bottom flask was charged with 2,5-dibromo-1-methyl-4-nitro-1H-imidazole 
(0.06 g, 0.21 mmol) and acetic acid (2 mL). The reaction was stirred, and potassium iodide 
(0.05 g, 0.32 mmol ) and sodium sulfite (0.04 g, 0.32 mmol) was added to the stirred solution. 
The reaction was heated to 125 OC and left to stir for 3 h. The reaction mixture was 
concentrated in vacuo to give a yellow powder. Water (5 mL) was added to this powder, and 
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the mixture was stirred for 10 minutes. Aqueous sodium metabisulfite (0.15 g, 0.78 mmol) 
was added and stirred for 30 minutes. The water phase was extracted with ethyl acetate (3 x 5 
mL), and the organic phase was washed with water (3 x 3 mL), before being concentrated in 
vacuo to obtain 2-bromo-1-methyl-4-nitro-1H-imidazole (0.04 g, 0.17 mmol, 80.62%) as a 





A 25 mL round bottom flask charged with 2-bromo-1-methyl-4-nitro-1H-imidazole (0.03 g, 
0.15 mmol) was flushed with argon before anhydrous THF (5 mL) was added. The reaction 
was cooled to -78OC, before n-BuLi (0.12 mL, 2.5M) was dropwise over 10 minutes and left 
to stir for 45 minutes. Cyclobutanone (0.01 mL, 0.16 mmol) was transferred to the flask and 
the reaction mixture was left to stir for another 45 minutes. The reaction mixture was then 
quenched with 3 mL water, and the water phase was extracted with ethyl acetate (3 x 10 mL). 




A 25 mL round bottom flask was charged with magnesium (0.006 g, 0.24 mmol) and flushed 
with argon. Iodine (1 chip) and 2-bromo-1-methyl-4-nitro-1H-imidazole (0.05 g, 0.24 mmol) 
was transferred to the flask. The reaction was started using a heat gun and left to stir for 45 






A 25 mL round bottom flask was charged with 2-bromo-1-methyl-4-nitro-1H-imidazole (0.05 
g, 0.24 mmol),  ethanol (5 mL), and Pd(OH)2/C (0.01 g). The mixture was subjected to an 
atmosphere of hydrogen for 2 h at room temperature. The mixture was filtered, and the 





A round bottom flask was charged with iron (0.04 g, 0.74 mmol), and 2-bromo-1-methyl-4-
nitro-1H-imidazole (0.05 g, 0.24 mmol) and a drop of acetic acid. A 9:1 mixture of ethanol 
and water (5 mL) was added. The reaction mixture was left to stir for 8 h. The solution was 
then heated to 70OC and left to stir for another 2 h. No product was yielded from the reaction. 
 
methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-4-carboxylate (17) 
 
A round bottom flask was charged with methyl 1-methyl-1H-imidazole-4-carboxylate (0.05 g, 
0.36 mmol) and flushed with argon before anhydrous THF (5 mL) was added. The reaction 
was cooled to -78OC, before n-BuLi (0.28 mL, 2.5M) was dropwise over 10 minutes and left 
to stir for 45 minutes. Cyclobutanone (0.03 mL, 0.39 mmol) was transferred to the flask and 
the reaction mixture was left to stir for another 45 minutes. The reaction mixture was then 
quenched with 3 mL water, and the water phase was extracted with ethyl acetate (3 x 5 mL). 






































Table 3. SMN-Luciferase Standard Conditions: 96-Well Format[3] 
Sequence Parameter Value Description 
1 Cells 100 µL 50 000 cells/well 96 TC–treated white plate 
2 Time 24 h 37 °C 5% CO2 
3 Compound 100 µL With compound 2× concentration 
4 Time 24 h 37 °C 5% CO2 
5 Remove media from 
wells 
  
6 Reagent 30 µL SteadyGlo or DualGlo reagent (Promega) 
7 Time 30 s Room temperature 
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